Medical devices, healthcare technology and the business of care
PMA SUPPLEMENT · P230001/S014

ColoSense

Geneoscopy, Inc. · Decision date Sep 8, 2026

FDA DECISIONP230001/S014

What did the FDA approve?

FDA records P230001/S014 as a supplement to PMA P230001, with the supplement type “Real-Time Process”. The recorded decision is approval, dated Sep 8, 2026.

FDA approval order statement

ColoSense Sample preservative shelf-life extension from the original PMA approval of 12 months to 18 months in this current supplement S014.
Regulatory pathway
PMA supplement
Supplement type
Real-Time Process
Clinical specialty
Pathology
Decision date
Sep 8, 2026
FDA change category
Labeling Change - Indications/instructions/shelf life/tradename

FDA source record

Regulatory record facts

Identifier
P230001/S014
Regulatory pathway
PMA supplement
Product code
SBB
Decision code
APPR
Decision date
Sep 8, 2026
Source update
Nov 9, 2026
Original record
Open FDA source record

About this medical device

FDA device category: System, Colorectal Neoplasia, RNA Markers and Hemoglobin detection.

Product code
SBB
FDA device class
3

For the original device and its historical approval scope, see PMA P230001. Subsequent supplements may change the device or its indications.

FDA decision timeline

  1. P230001/S014 received

    Application receipt date recorded by FDA.

  2. P230001/S014 · FDA decision

    Real-Time Process

Timeline entries are records held by MedtechLedger for P230001. View FDA’s full supplement list.

Related devices and submissions

Same PMA: P230001

Product / regulatory recordCompanyPathwayDecision dateSource
ColoSenseP230001
Geneoscopy, Inc.PMA approvalMay 3, 2024FDA

Explore the linked device profile

Regulatory context

A PMA supplement records a change to a device with an existing premarket approval. The supplement’s approval applies to the change described in that submission.

FDA describes the real-time supplement process as a review route for minor changes to a device, including certain design, software, sterilization or labeling changes.

Read our guide to FDA clearance and approval · FDA’s explanation of this pathway

Manufacturer intelligence

Geneoscopy, Inc.

Headquarters
Not reported
Brand website
Not reported
FDA applicant address
2220 Welsch Industrial Ct., St. Louis, MO, 63146

Sources and methodology

FDA fields and approval-order wording are presented as source information. MedtechLedger explanations are identified separately and describe the scope of the recorded decision. Indications from an original PMA are historical unless confirmed against subsequent labeling and supplements.

How we use FDA records